Syndax is developing a pipeline of combination therapies in multiple cancer indications. Its lead product candidate, Entinostat, is currently being evaluated in a Phase III clinical trial for advanced HR+ breast cancer. Syndax advanced Entinostat to this pivotal trial based on positive Phase IIb results, meeting endpoints with statistical significance in both PFS and OS.